Radiopharmaceutical firm DraxImage of Kirkland, Quebec, and biopharmaceutical firm Cytogen of Princeton, NJ, have terminated agreements for DraxImage’s BrachySeed I-125 and BrachySeed Pd-103 products. The companies have mutually agreed to terminate the BrachySeed agreements, maintain the confidentiality of each other's proprietary information, and release one another from liability with respect to any claims under the agreements.
The two firms also said they are coordinating efforts for an orderly transition of the brachytherapy business in order to ensure that customer service is maintained, and that no patient care is disrupted as a result of the changes.
By AuntMinnie.com staff writers
April 9, 2003
Related Reading
DraxImage begins U.S. shipments of I-131 kit, April 3, 2003
Cytogen 2002 loss grows despite revenue gains, February 26, 2003
DraxImage gets clearance for radiotherapeutic kit, January 29, 2003
Cytogen, Draxis dispute heats up, January 28, 2003
Production of palladium BrachySeed version halted, January 17, 2003
Copyright © 2003 AuntMinnie.com
